Sign in
Taking people in United StatesNo phase

Online Program Helps Melanoma Survivors Check Their Own Skin

Tests an online tool that teaches adults with melanoma how to check their own skin.

Key facts

Who runs it
Rutgers, The State University of New Jersey
Where
New Brunswick, United StatesSee the site
Trial code
Registry title
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
Status
Recruiting
People taking part
385 people, planned
Started
6 Mar 2023
Expected to end
31 Mar 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • MySmartSkin enhancement
  • Educational webpage on Skin Self-Examination
  • Assess implementation outcomes
Record updated
28 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who had melanoma surgery in the past and currently show no sign of cancer. It tests an online skin self-exam program.

Age
18 years or older
Sex
All sexes can join
Disease stage
Primary cutaneous malignant melanoma, stage 0-III, with no current evidence of cancer
Earlier treatment
Melanoma surgery between three months and five years ago

Main reasons for not taking part

  • Children
  • People who already check their whole body for skin changes at least once every three months
  • People without internet access
  • People who cannot speak or read English
  • People who cannot give informed consent

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Diagnosis of primary pathologic stage 0-III cutaneous malignant melanoma
  • Three months to five years post-surgery
  • No current evidence of cancer
  • Not adherent to thorough SSE (i.e., did not check entire body at least once during the past three months)
  • ≥ 18 years old
  • Internet access
  • Able to speak/read English
  • Able to provide informed consent

Who cannot take part

  • Children

Where in United States

  • Rutgers Cancer Institute of New JerseyNew Brunswick, United StatesContact: Sharon Manne, PhDTaking people

About the trial

What the trial wants to find out

This project, mySmartSkin (MSS), includes an innovative Type 1 hybrid effectiveness-implementation trial designed to enhance the effects of MSS and simultaneously assess key implementation outcomes (e.g., cost, adoption) as well as contextual factors important for scale-up in community and health care settings where melanoma survivors receive follow-up care. A type 1 hybrid effectiveness-implementation design allows us to engage multilevel stakeholders throughout this process, evaluate the effectiveness of the enhanced MSS, and identify critical factors for wide-scale implementation. Aim 1 will focus on enhancing the previous version of MSS by collaborating with multi-level stakeholders in qualitative interviews and usability testing. Aim 2 will evaluate the effects of enhanced MSS on thorough skin-self examinations (SSE) in a randomized-control trial (RCT) and examine its impact on the diagnosis of new/recurrent melanomas. Aim 3 will focus on assessing selected implementation outcomes and identify factors relevant to future scale-up for widespread dissemination and implementation.

The 3 groups in the trial

  • Enhance MSS using multi-level stakeholder collaboration (Mo.1-15)Treatment being tested

    Enhancements of MSS to increase intervention effects - theory - based strategies (PHM), (BCT)

    Treatment: MySmartSkin enhancement

  • Involves the longitudinal RCT comparing behavioral outcomes and effectiveness (Mo.16 -60)Treatment being tested

    RCT of enhanced MSS testing effectiveness (thorough SSE, sun protection behavior Involves the longitudinal RCT comparing behavioral outcomes and effectiveness of enhanced MSS versus an educational webpage on SSE as well as new recurrences/melanomas

    Treatment: Educational webpage on Skin Self-Examination

  • Aim 3: Assess implementation outcomes, identify factors relevant for future scale-up (Mo.17-60)Existing treatment, for comparison

    Assessment of implementation outcomes and key contextual factors from the perspective of multi - level stakeholders

    Treatment: Assess implementation outcomes

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Digital Intervention to Improve Skin Self-examination Among Melanoma Survivors
Plain-language title
Online Program Helps Melanoma Survivors Check Their Own SkinGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
28 July 2026